Investigational drug · Phase 2
NAV-240
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hidradenitis Suppurativa (HS).
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "NAV-240"
First trial start
2026
Jan 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NAV-240", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa (HS)
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "NAV-240" as an intervention, largest first.
- A Study to Assess NAV-240 in Adult Participants With Hidradenitis SuppurativaPivotal-lookingRecruiting
Navigator Medicines, Inc.Industry
NCT07384975 · 150 participants (planned) · Start Jan 5, 2026 · Primary completion Sep 2027
Drug: NAV-240; Placebo to match NAV-240 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Maitland, Florida · 41 sites in all
Navigator Medicines, Inc.Industry
NCT06181786 · 40 participants · Start Nov 22, 2023 · Primary completion Sep 4, 2024
Drug: NAV-240; Placebo · For: Healthy
Sites: Miami, Florida
Navigator Medicines, Inc.Industry
NCT06933043 · 24 participants · Start May 20, 2025 · Primary completion Nov 20, 2025
Drug: NAV-240; Placebo · For: Healthy Volunteers
Sites: Brisbane, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hidradenitis Suppurativa (HS)
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- LT-002-158Phase 23 trials
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- ORKA-002Phase 23 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)
- CIT-013Phase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- CIT-013 dosePhase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- SL-325Phase 22 trials
Shattuck Labs, Inc. · Crohn's Disease, Hidradenitis Suppurativa (HS)
- SPY002-072SPY072Phase 22 trials
Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.